These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 526624)

  • 21. [Experimental principles of immunotherapy in malignant tumors using microbial substances. 2. Effect of streptococci on ascites-rethotelsarcoma of the mouse in vitro].
    Huth E
    Fortschr Med; 1977 Jun; 95(21):1409-12. PubMed ID: 873421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of antibodies to synthetic nerve growth factor (NGF) and proNGF peptides.
    Ebendal T; Persson H; Larhammar D; Lundströmer K; Olson L
    J Neurosci Res; 1989 Mar; 22(3):223-40. PubMed ID: 2468788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic thermochemotherapy in a rat model.
    Rotstein LE; Daly J; Rozsa P
    Can J Surg; 1983 Mar; 26(2):113-6. PubMed ID: 6824995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.
    Wondergem J; Stephens LC; Strebel FR; Baba H; Ohno S; Siddik ZH; Newman RA; Bull JM
    Cancer Res; 1991 Jul; 51(13):3559-67. PubMed ID: 2054792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Purification and characterization of Fab fragments from anti-mouse NGF polyclonal antibodies.
    Callegaro L; Skaper SD; Vantini G; Benvegnù D; Di Martino A; Schiavo N; Triban C; Minozzi C; Leon A
    J Mol Recognit; 1990; 3(5-6):187-91. PubMed ID: 2096885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma.
    Evans R; Duffy T
    J Immunol; 1985 Jun; 134(6):4255-60. PubMed ID: 3872913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of sensitive enzyme immunoassay for human nerve growth factor.
    Murase K; Furukawa Y; Iwane M; Hayashi K
    Biochem Int; 1991 Sep; 25(1):29-34. PubMed ID: 1772446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth.
    Forni G; Musso T; Santoni A; Giovarelli M
    Prog Clin Biol Res; 1987; 244():105-14. PubMed ID: 2958866
    [No Abstract]   [Full Text] [Related]  

  • 29. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
    Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nerve growth factor and cytokines mediate lymphoid tissue-induced neurite outgrowth from mouse superior cervical ganglia in vitro.
    Kannan Y; Bienenstock J; Ohta M; Stanisz AM; Stead RH
    J Immunol; 1996 Jul; 157(1):313-20. PubMed ID: 8683132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody to NGF inhibits collateral sprouting of septohippocampal fibers following entorhinal cortex lesion in adult rats.
    Van der Zee CE; Fawcett J; Diamond J
    J Comp Neurol; 1992 Dec; 326(1):91-100. PubMed ID: 1479072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production and characterization of a monoclonal antibody against nerve growth factor (NGF) which recognizes rodent and human NGF.
    Vigneti E; Bracci-Laudiero L; Aloe L
    Year Immunol; 1993; 7():146-9. PubMed ID: 8372503
    [No Abstract]   [Full Text] [Related]  

  • 33. S-180 cells secrete nerve growth factor protein similar to 7S-nerve growth factor.
    Barklis E; Perez-Polo JR
    J Neurosci Res; 1981; 6(1):21-36. PubMed ID: 7218372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fundamental study on hyperthermic chemotherapy using adriamycin-loaded hydroxyapatite].
    Nakatani S; Kunieda K; Seki T; Wakabayashi M; Inoue K; Nagata K; Murata T; Tanaka Y; Sougawa M; Kimura R
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1644-7. PubMed ID: 1326924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virologic and immunologic properties and response to daunomycin and adriamycin of a non-regressing mouse tumor derived from MSV-induced sarcoma.
    Giuliani F; Casazza AM; Di Marco A
    Biomedicine; 1974 Nov; 21(11):435-9. PubMed ID: 4377230
    [No Abstract]   [Full Text] [Related]  

  • 36. Transferrin directed delivery of adriamycin to human cells.
    Singh M; Atwal H; Micetich R
    Anticancer Res; 1998; 18(3A):1423-7. PubMed ID: 9673350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An approach for the generation of effector lymphocytes from tumor-bearing hosts for the adoptive immunotherapy of established tumors.
    Shu SY; Chou T
    Prog Clin Biol Res; 1987; 244():27-37. PubMed ID: 3498953
    [No Abstract]   [Full Text] [Related]  

  • 38. gamma-Interferon plays a key role in T-cell-induced tumor regression.
    Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
    Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct antitumor effect of cepharanthin and combined effect with adriamycin against Ehrlich ascites tumor in mice.
    Asaumi J; Nishikawa K; Matsuoka H; Iwata M; Kawasaki S; Hiraki Y; Nishijima K
    Anticancer Res; 1995; 15(1):67-70. PubMed ID: 7733643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic cross-reactivity of nerve growth factors from diverse source: activity versus toxicity of NGF.
    Lipps BV
    J Nat Toxins; 2002 Feb; 11(1):57-62. PubMed ID: 11829061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.